Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy

Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy

<p><strong>Background</strong> Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells facilitate tumor immune evasion by forming a suppressive tumor microenvironment. Therefore, immune therapies promoting T<sub>reg</sub>&nbs...

Bibliografiset tiedot
Päätekijät:	Deng, B, Yang, B, Chen, J, Wang, S, Zhang, W, Guo, Y, Han, Y, Li, H, Dang, Y, Yuan, Y, Dai, X, Zang, Y, Li, Y, Li, B
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	BMJ Publishing Group 2022

Samankaltaisia teoksia

Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
Tekijä: Bin Li, et al.
Julkaistu: (2022-07-01)

Correction: Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
Julkaistu: (2022-10-01)

USP21 prevents the generation of T-helper-1-like Treg cells
Tekijä: Li, Y, et al.
Julkaistu: (2016)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
Tekijä: Lin X, et al.
Julkaistu: (2021-03-01)

USP21 prevents the generation of T-helper-1-like Treg cells
Tekijä: Yangyang Li, et al.
Julkaistu: (2016-11-01)

Antioxidant properties of two novel lipophilic gallic acid derivatives
Tekijä: T.M. Olajide, et al.
Julkaistu: (2022-09-01)

MCT4 blockade increases the efficacy of immune checkpoint blockade
Tekijä: Christian Schmidl, et al.
Julkaistu: (2023-10-01)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Tekijä: Ira Mellman, et al.
Julkaistu: (2022-04-01)

Neoadjuvant immune checkpoint blockade triggers persistent and systemic Treg activation which blunts therapeutic efficacy against metastatic spread of breast tumors
Tekijä: Olga S. Blomberg, et al.
Julkaistu: (2023-12-01)

Influence of Treg cells and HBV genotype on sustained response and drug resistance in the treatment with nucleoside drugs
Tekijä: Y.R. Zhang, et al.

Metabolic checkpoints in neurodegenerative T helper 17 (TH17) and neuroregenerative regulatory T (Treg) cells as new therapeutic targets for multiple sclerosis
Tekijä: Hongxing Shen, et al.
Julkaistu: (2020-01-01)

Recombinant Keratin-Chitosan Cryogel Decorated with Gallic Acid-Reduced Silver Nanoparticles for Wound Healing
Tekijä: Miao N, et al.
Julkaistu: (2024-10-01)

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies
Tekijä: Jose M. González-Navajas, et al.
Julkaistu: (2021-02-01)

Costimulation blockade and Tregs in solid organ transplantation
Tekijä: Moritz Muckenhuber, et al.
Julkaistu: (2022-09-01)

Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy
Tekijä: Donghwan Jeon, et al.
Julkaistu: (2024-05-01)

LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade
Tekijä: Sheng, W, et al.
Julkaistu: (2018)

An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment
Tekijä: Leena Halim, et al.
Julkaistu: (2017-07-01)

Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
Tekijä: Zhijia Xia, et al.
Julkaistu: (2023-07-01)

Efficacy and safety of immune checkpoint blockade for brain metastases
Tekijä: Maya Harary, et al.
Julkaistu: (2019-06-01)

Predictors of responses to immune checkpoint blockade in advanced melanoma
Tekijä: N. Jacquelot, et al.
Julkaistu: (2017-09-01)

Early C‐reactive Protein Kinetics Predict Response to Immune Checkpoint Blockade in Unresectable Hepatocellular Carcinoma
Tekijä: Qin Q, et al.
Julkaistu: (2023-11-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
Tekijä: Li XY, et al.
Julkaistu: (2022-04-01)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
Tekijä: Firas Y. Kreidieh, et al.
Julkaistu: (2023-07-01)

Multicomponent Precipitation and Strengthening in Intermetallic-Strengthened Alloys
Tekijä: J.Y.C. Fang, et al.
Julkaistu: (2022-06-01)

Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Tekijä: Yang X, et al.
Julkaistu: (2023-02-01)

Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
Tekijä: Zhang, C, et al.
Julkaistu: (2018)

ANALYSIS OF T HELPER SUBPOPULATIONS (Th1, Th2, Treg, Th17, ACTIVATED T-HELPERS) BY MEANS OF FLOW CYTOMETRY
Tekijä: S. V. Khaidukov, et al.
Julkaistu: (2014-07-01)

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
Tekijä: Gao Y, et al.
Julkaistu: (2021-08-01)

Multifunctional Nanoplatform-Mediated Chemo-Photothermal Therapy Combines Immunogenic Cell Death with Checkpoint Blockade to Combat Triple-Negative Breast Cancer and Distant Metastasis
Tekijä: Zhu H, et al.
Julkaistu: (2023-06-01)

Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
Tekijä: Joseph Markowitz, et al.
Julkaistu: (2024-09-01)

Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy
Tekijä: Meng Chen, et al.
Julkaistu: (2023-03-01)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
Tekijä: Li J, et al.
Julkaistu: (2023-04-01)

897-F Wnt inhibition improves efficacy of immune checkpoint blockade in glioblastoma
Tekijä: Dai Fukumura, et al.
Julkaistu: (2023-11-01)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Tekijä: Douglas B. Fox, et al.
Julkaistu: (2023-03-01)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
Tekijä: Jun-Yan Li, et al.
Julkaistu: (2021-02-01)

Crack-arresting and Strengthening Mechanism of Hybrid Fiber Reinforced Polymer Sheets in Strengthening of Reinforced Concrete Beams
Tekijä: X. B. He, et al.
Julkaistu: (2013-07-01)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
Tekijä: Liu, Y, et al.
Julkaistu: (2021)

Immune checkpoint blockade in HIV
Tekijä: Celine Gubser, et al.
Julkaistu: (2022-02-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
Tekijä: William L. Redmond, et al.
Julkaistu: (2023-02-01)

The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer
Tekijä: Xiangzheng Liu, et al.
Julkaistu: (2021-08-01)